Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference42 articles.
1. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD et al. (2000). Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342: 613–619.
2. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA et al. (2006). Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103: 5941–5946.
3. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J et al. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101: 8705–8708.
4. Depper JM, Leonard WJ, Kronke M, Noguchi PD, Cunningham RE, Waldmann TA et al. (1984). Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol 133: 3054–3061.
5. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C et al. (2000). The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 69: 1867–1872.
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献